Supriya Lifescience · NSE: SUPRIYA · BSE: 543434
Q3 FY26 results · Oct–Dec 2025
Supriya Lifescience reported revenue from operations of ₹206.44 crore (up 11.2% from Q3 FY25) and net profit of ₹49.67 crore (up 6.2% from Q3 FY25) for Q3 FY26 (Oct–Dec 2025), on a standalone basis.
| Item | Q3 FY26 | Q3 FY25 | YoY | Q2 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 206.44 | 185.65 | +11.2% | 199.83 | +3.3% |
| Other income | 2.61 | 2.10 | +24.5% | 2.73 | −4.2% |
| Total income | 209.05 | 187.75 | +11.3% | 202.56 | +3.2% |
| Profit before tax | 66.92 | 62.58 | +6.9% | 68.32 | −2.0% |
| Net profit for the period | 49.67 | 46.78 | +6.2% | 50.43 | −1.5% |
| EPS, basic (₹) | 6.17 | 5.82 | +6.0% | 6.27 | −1.6% |
| Net margin (%) | 24.1 | 25.2 | 25.2 |
Standalone
- Filed with BSE
- 09 Feb 2026, 20:01 IST
- Board meeting
- 09 Feb 2026
- Period
- 01 Oct 2025 to 31 Dec 2025
- Review status
- Unaudited
- Source
- XBRL filing on BSE